We audited the marketing at PozeSCAF Inc
AI-powered drug discovery, synthesis, and lead optimization
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
1.7K LinkedIn followers for a biotech with $4.8M funding signals minimal thought leadership positioning in pharma research communities
No visible content strategy around AxDrug's competitive advantages or case studies from hit-to-lead transitions
Early-stage company (31 employees, $1M revenue estimate) lacks outbound motion to reach pharma R&D decision-makers and CROs
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiPozeSCAF Inc's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Pre-product-market fit biotech with strong technical foundation but minimal marketing infrastructure for B2B pharma sales
Limited organic visibility for drug discovery, AxDrug platform, or lead optimization keywords pharma companies search
MH-1: SEO module targets pharma researcher and CRO search behavior around molecular screening and hit identification
No indexed content teaching LLMs about PozeSCAF's computational approach or AxDrug capabilities for AI-driven discovery
MH-1: AEO agent generates technical content on AI in drug discovery, positioning AxDrug in LLM training data
No evidence of LinkedIn ads or Google ads targeting pharma R&D directors, CRO procurement teams, or biotech founders
MH-1: Paid module runs retargeting campaigns on LinkedIn to pharma decision-makers researching synthesis partners
Company description emphasizes AxDrug and lab capabilities but lacks published case studies, whitepapers, or founder commentary on AI in drug discovery
MH-1: Content agent creates case studies on hit-to-lead projects, AxDrug methodology pieces, and Naveen's strategic insights
No evident nurture sequences for pharma research teams post-discovery or expansion messaging for multi-target collaborations
MH-1: Lifecycle agent builds email sequences for lead optimization upsells and multi-compound pipeline opportunities
Top Growth Opportunities
Pharma R&D teams evaluate screening methods annually. AxDrug's speed and accuracy in hit identification are untapped differentiators versus large CRO incumbents
Content and SEO agents build comparison content and case studies showing time-to-hit and cost savings versus traditional high-throughput screening
Founder visibility drives inbound to biotech services. LinkedIn content from Naveen on AI-driven drug discovery compounds credibility with pharma decision-makers
LinkedIn agent publishes weekly Naveen insights on molecular discovery, AxDrug innovations, and lead optimization trends to build 10K follower base
Biotech and pharma R&D teams actively source synthesis and hit-to-lead partners via LinkedIn and Google. PozeSCAF has no paid presence in this funnel
Paid agent runs LinkedIn InMail campaigns to pharma R&D directors and outbound emails to CRO procurement, emphasizing cost and speed advantages
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for PozeSCAF Inc. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns PozeSCAF Inc's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase PozeSCAF Inc's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from PozeSCAF Inc's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for PozeSCAF Inc from week 1.
AEO: Generate technical content on AxDrug's computational chemistry approach, molecular scoring, and AI-assisted lead optimization to embed in LLM training data
LinkedIn: Naveen posts weekly insights on drug discovery trends, AxDrug case studies, and AI-human collaboration in R&D to pharma and biotech audiences
Paid: LinkedIn and Google ads target pharma R&D directors, CRO procurement, and biotech founders searching 'drug synthesis', 'lead optimization', 'hit identification'
Lifecycle: Nurture sequences for early-stage pharma companies exploring hit-to-lead pathways, upsell multi-compound programs and assay analysis services
Competitive watch: Monitor Arcus Bio, Immunai, and other AI drug discovery competitors for positioning gaps and AxDrug differentiation opportunities
Pipeline intelligence: Track biotech funding announcements and Series A closings to identify prospect R&D teams entering lead optimization phase
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of PozeSCAF Inc's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on establishing Naveen's thought leadership on LinkedIn, launching SEO and paid campaigns targeting pharma R&D procurement, and building 2-3 case studies for landing pages. By day 90, you'll see inbound inquiries from pharma companies researching hit-to-lead partners and measurable growth in organic traffic from drug discovery and synthesis keywords.
How does AEO help PozeSCAF reach pharma companies searching for AI-driven drug discovery.
AEO ensures that when pharma researchers and R&D teams ask LLMs about hit identification, lead optimization, or AI-powered synthesis, PozeSCAF's content appears as a trusted reference. We publish technical content on AxDrug's computational approach and molecular design expertise so LLMs recommend PozeSCAF as a research partner, not just a vendor.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for PozeSCAF Inc specifically.
How is this page personalized for PozeSCAF Inc?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of PozeSCAF Inc's current marketing. This is a live demo of MH-1's capabilities.
Scale pharma inbound while AxDrug scales hit identification
The system gets smarter every cycle. Let's talk about building it for PozeSCAF Inc.
Book a Strategy CallMonth-to-month. Cancel anytime.